WC Walker & Associates Inc. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

WC Walker & Associates Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,778 shares of the company’s stock after buying an additional 242 shares during the quarter. Johnson & Johnson comprises about 1.4% of WC Walker & Associates Inc.’s holdings, making the stock its 24th biggest holding. WC Walker & Associates Inc.’s holdings in Johnson & Johnson were worth $2,545,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc raised its position in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC raised its position in Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Johnson & Johnson by 0.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after purchasing an additional 24,505 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Atlantic Securities dropped their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective on the stock. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.42.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the company’s stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares in the company, valued at $7,336,927.11. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 300,750 shares of company stock worth $52,311,677. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $173.43 on Friday. The stock has a market cap of $453.43 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 3.29 and a beta of 0.56. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company’s 50-day moving average price is $176.32 and its 200 day moving average price is $171.51. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.60 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.